Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Artelo Biosciences Inc (ARTL)

Artelo Biosciences Inc (ARTL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 23,882
  • Shares Outstanding, K 15,712
  • Annual Sales, $ 0 K
  • Annual Income, $ -4,650 K
  • 60-Month Beta 2.43
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.64
Trade ARTL with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 02/28/21
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.40
  • Growth Rate Est. (year over year) +249,850.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3900 +1.44%
on 04/12/21
2.1800 -35.32%
on 03/19/21
-0.5600 (-28.43%)
since 03/12/21
3-Month
0.8800 +60.23%
on 01/28/21
3.6700 -61.58%
on 02/12/21
+0.4465 (+46.34%)
since 01/12/21
52-Week
0.4510 +212.64%
on 11/02/20
3.6700 -61.58%
on 02/12/21
+0.4000 (+39.60%)
since 04/09/20

Most Recent Stories

More News
Artelo Biosciences Doses First Patient in CAReS Study with ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss

Initial safety data expected from CAReS Study before end of 2021

ARTL : 1.3800 (-9.21%)
Cancer Anorexia Market Insights Report 2021 - Major Players are NGM Biopharmaceuticals, Artelo Biosciences and Helsinn Healthcare

The "Cancer Anorexia - Market Insight, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

ARTL : 1.3800 (-9.21%)
Artelo Biosciences Accepted into the Alderley Park Oncology Development Program for FABP5 Inhibitor Biomarker Development

Detection of elevated FABP5 associated with additional tumor types suggests the target for ART26.12 may be more broadly relevant in cancer therapy

ARTL : 1.3800 (-9.21%)
Thinking about buying stock in American Resources, Sundial Growers, Hexo Corp, AMC Entertainment, or Artelo Biosciences?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AREC, SNDL, HEXO, AMC, and ARTL.

AC : 34.49 (-0.75%)
AREC : 3.71 (-0.27%)
ARTL : 1.3800 (-9.21%)
SNDL : 0.9465 (-5.35%)
AMC : 8.91 (-5.41%)
HEXO : 5.94 (-8.05%)
Artelo Biosciences, Inc. to Present at the Q1 Virtual Investor Summit on March 23rd

via InvestorWire - Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system,...

ARTL : 1.3800 (-9.21%)
Artelo Biosciences Appoints Finance and Healthcare Industry Executive Tamara A. Seymour to Board of Directors

Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system,...

ARTL : 1.3800 (-9.21%)
Artelo Biosciences to Present at the H.C. Wainwright Global Life Sciences Conference on March 9th

Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced...

ARTL : 1.3800 (-9.21%)
Artelo Biosciences Announces Positive Pre-Clinical Data Associated with Proprietary CBD Cocrystal

Artelo Biosciences, Inc. (NASDAQ: ARTL) today announced that Saoirse O'Sullivan, Ph.D., Professor of Pharmacology and Scientific Advisor to Artelo, along with Ryan Maguire and Dr. Timothy England of the...

ARTL : 1.3800 (-9.21%)
Artelo Biosciences Announces Appointment of Andrew Yates, Ph.D. as Senior Vice President and Chief Scientific Officer

Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid...

ARTL : 1.3800 (-9.21%)
Thinking about buying stock in Artelo Biosciences, Xeris Pharmaceuticals, Inovio Pharmaceuticals, Novan, or Fisker?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ARTL, XERS, INO, NOVN, and FSR.

ARTL : 1.3800 (-9.21%)
INO : 8.25 (-5.39%)
NOVN : 1.4000 (-5.41%)
XERS : 4.03 (-4.73%)
FSR : 14.81 (-3.83%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Artelo Biosciences Inc. is a biopharmaceutical company. It is engaged in development and commercialization of proprietary therapeutics targeting the endocannabinoid system. The company's product pipeline consists of ART27.13, ART12.11 and ART26.12 which are in clinical stage. Artelo Biosciences Inc....

See More

Key Turning Points

3rd Resistance Point 1.6412
2nd Resistance Point 1.6089
1st Resistance Point 1.5645
Last Price 1.3800
1st Support Level 1.4878
2nd Support Level 1.4555
3rd Support Level 1.4111

See More

52-Week High 3.6700
Fibonacci 61.8% 2.4403
Fibonacci 50% 2.0605
Fibonacci 38.2% 1.6807
Last Price 1.3800
52-Week Low 0.4510

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar